A Study to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above (Complementary Study to DAN-RSV)

First published 04/06/2025

Last updated 02/07/2026

EU PAS number:

EUPAS1000000480

Study

Ongoing

Download as PDF

Documents

Study protocol

No information provided.

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

A Study to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above (Complementary Study to DAN-RSV)

Secondary tabs

Share this page